APR-003 is under clinical development by Apros Therapeutics and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APR-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APR-003 overview

APR-003 is under development for the treatment of colorectal cancer, liver cancer and hepatitis B. It is administered by oral route. It acts by targeting toll like receptor 7 (TLR7).

Apros Therapeutics overview

Apros Therapeutics is a drug discovery and development company focused on tissue-targeted small molecule innate immune agonists to increase tumor immunogenicity turning cold tumors hot. Apros Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of APR-003’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.